drugset / Trial / NCT04499235

A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid

NCT04499235

Phase 2 Terminated 6 enrolled Alkahest, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the therapeutic effect and safety of adjunctive AKST4290 in subjects with bullous pemphigoid (BP).

Timeline

Start
2020-01-30
Primary completion
2021-03-29
Completion
2021-04-14

Drugs

EvaluationDrugModalityDoseRoute
Subject LAZUCIRNON Small molecule 400 mg Oral
Background Mometasone furoate Other / unclassified Topical

Indications